Back
IDEXX Laboratories Quote, Financials, Valuation and Earnings
NOW is the time to get in on this trillion-dollar megatrend
Get it here.
Buy
62
IDXX
IDEXX Laboratories
Last Price:
499.36
Seasonality Move:
8.9%
7 Day Trial
ALL ACCESS PASS
$
7
Election Shock on August 19th?
Click here now to see the evidence I've gathered.IDEXX Laboratories Price Quote
$499.36
+0.06 (+2.07%)
(Updated: April 27, 2024 at 6:08 AM ET)
IDEXX Laboratories Key Stats
Buy
62
IDEXX Laboratories (IDXX)
is a Buy
Day range:
$484.03 - $500.48
52-week range:
$372.50 - $583.39
Dividend yield:
0%
P/E ratio:
49.63
P/S ratio:
11.45
P/B ratio:
27.95%
Volume:
529.8K
Avg. volume:
428.7K
1-year change:
3.71%
Market cap:
$41.5B
Revenue:
$3.7B
EPS:
$10.07
How Much Does IDEXX Laboratories Make?
-
How Much Are IDEXX Laboratories's Sales Annually?
IDXX Revenues are $3.7B -
How Much Profit Does IDEXX Laboratories's Make A Year?
IDXX net income is $845M
Is IDEXX Laboratories Growing As A Company?
-
What Is IDEXX Laboratories's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0.09% -
What Is IDEXX Laboratories's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0.13%
IDEXX Laboratories Stock Price Performance
-
Did IDEXX Laboratories Stock Go Up Last Month?
IDEXX Laboratories share price went down by -5.9% last month -
Did IDXX's Share Price Rise Over The Last Year?
IDXX share price rose by 3.71% over the past 1 year
What Is IDEXX Laboratories 52-Week High & Low?
-
What Is IDEXX Laboratories’s 52-Week High Share Price?
IDEXX Laboratories has traded as high as $583.39 over the past 52 weeks -
What Is IDEXX Laboratories’s 52-Week Low Share Price?
IDEXX Laboratories has traded as low as $372.50 over the past 52 weeks
IDEXX Laboratories Price To Free Cash Flow
-
Is IDEXX Laboratories Stock Overvalued?
IDEXX Laboratories is trading at a price to free cash flow ratio of 54.25 -
Is IDEXX Laboratories Stock Undervalued?
IDEXX Laboratories EV to Free Cash Flow ratio is 54.32 -
What Is IDEXX Laboratories’s Price Earnings Growth Ratio?
IDXX PEG ratio is 1.95 -
Is IDEXX Laboratories Trading At A Premium To Earnings?
IDEXX Laboratories EV to EBIT ratio is 38.07
Is It Risky To Buy IDEXX Laboratories?
-
How Much Debt Does IDEXX Laboratories Have?
Total long term debt quarterly is $947.9M -
How Much Cash Does IDEXX Laboratories Have?
Cash and short term investments quarterly total is $453.9M -
What Is IDEXX Laboratories’s Book Value Per Share?
Book value per share is 17.88
Is IDEXX Laboratories Cash Flow Positive?
-
What Is IDXX Cash Flow From Operations?
Cash flow from operations (TTM) is $906.5M -
What Is IDEXX Laboratories’s Cash Flow From Financing?
Cash flow from financing (TTM) is -$442M -
What Is IDEXX Laboratories’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$125.3M
IDEXX Laboratories Return On Invested Capital
-
Is Management Doing A Good Job?
IDXX return on invested capital is 38.84% -
What Is IDEXX Laboratories Return On Assets?
ROA measures how assets are converting to revenues and is 28.6% -
What Is IDXX Return On Equity?
ROE is a measure of profitability and is 79.34%
IDEXX Laboratories Earnings Date & Stock Price
-
What Is IDEXX Laboratories's Stock Price Today?
A single share of IDXX can be purchased today for 499.30 -
What Is IDEXX Laboratories’s Stock Symbol?
IDEXX Laboratories trades on the nasdaq under the ticker symbol: IDXX -
When Is IDEXX Laboratories’s Next Earnings Date?
The next quarterly earnings date for IDEXX Laboratories is scheduled on May 1, 2024 -
When Is IDXX's next ex-dividend date?
IDEXX Laboratories's next ex-dividend date is April 27, 2024 -
How To Buy IDEXX Laboratories Stock?
You can buy IDEXX Laboratories shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
IDEXX Laboratories Competitors
-
Who Are IDEXX Laboratories's Competitors?
Below is a list of companies who compete with IDEXX Laboratories or are related in some way:
IDEXX Laboratories Dividend Yield
Data Unavailable
IDEXX Laboratories Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 13.17% | 9.39% |
| Revenue: | 8.81% | 1.24% |
Analyst Recommendations
| Buy Recommendations: | 2 |
|---|---|
| Hold Recommendations: | 4 |
| Sell Recommendations: | 1 |
| Price Target: | 585.81 |
| Upside from Last Price: | 17.33% |